Breakthrough pain in cancer patients: Pathophysiology and treatment

Cancer Treatment Reviews

Volumn 24, Issue 6, 1998, Pages 425-432

  Mercadante, S ^a,b,d   Arcuri, E ^c  

^a SAMOT Onlus   (Italy)

^b Dept Anesthesia and Intensive Care   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d Dept Pain Relief Palliative Care S ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTITUSSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; FENTANYL; HYDROGEN PEROXIDE; KETAMINE; LAXATIVE; LOCAL ANESTHETIC AGENT; MORPHINE; NITROUS OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID;

BONE METASTASIS; CANCER PAIN; DOSE CALCULATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEUROPATHY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOTHERAPY; REVIEW; TREATMENT PLANNING;

EID: 0032454825     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90005-6     Document Type: Article

References (55)

1. Hanks GW, Portenoy RK, MacDonald N, et al. Difficult pain problems. In: Doyle D, Hanks GW, MacDonald N. (Eds), Oxford textbook of palliative medicine, Oxford Medical Publications, Oxford, 1993, pp 257-274.
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990; 41:273-281.
3. Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 1997; 243 (suppl. 16):7-12.
4. Mercadante S, Maddaloni S, Roccella S et al. Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992; 50:151-155.
5. Bruera E, Schoeller T, Wenk R, et al. A prospective multi-center assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995; 10:348-355.
6. Banning A, Sjogren P, Henriksen H. Treatment outcome in a multidisciplinary cancer pain clinic. Pain 1991; 47:129-134.
7. Gourlay GK, Plummer JL, Cherry DA. Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. 1995; 61: 375-381.
8. Bruera E, MacMillian K, Kuehn N, et al. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain 1992; 49:311-314.
9. Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997; 14:63-73.
10. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997; 69:295-302.
11. Coyle N, Portenoy RK. Infection as a cause of rapidly increasing pain in cancer patients. J Pain Symptom Manage 1991; 6:266-269.
12. Mackey JR, Birchall I, MacDonald N. Occult infection as a cause of hip pain in a patient with metastatic breast cancer. J Pain Symptom Manage 1995; 10:569-572.
13. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
14. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer. Pain 1998; 74:5-9.
15. Sylvester RK, Levitt R, Steen PD. Opioid-induced muscle activity: implications for managing chronic pain. Ann Pharmacother 1995; 29:1118-1121.
16. Mercadante S. What is the definition of breakthrough pain? Pain 45:107, 1991.
17. McQuay HJ, Jadad AR. Incident pain. In: Cancer Surveys, Vol. 21. Palliative Medicine: Problem areas in Pain and Symptom Management, G.W. Hanks ed. Cold Spring Harbor Laboratory Press, New York, 1994, pp 17-24.
18. Bruera E, Fainsinger R, MacEachern T, et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992; 50:75-77.
19. Ripamonti C, Bruera E. Current status of patient-controlled analgesia in cancer patients. 1997; 11:373-380.
20. Walsh T, Smyth EM, Currie K, et al. A pilot study, reviw of the literature, and dosing guidelines for patient-controlled analgesia using subcutaneous morphine sulphate for chronic cancer pain. 1992; Palliat Med 6:217-226.
21. Ferrell BR, Nash CC, Warfiled C. The role of patient-controlled analgesia in the management of cancer pain. J Pain Symptom Manage 1992; 7:149-154.
22. Coluzzi PH. Oral patient-controlled analgesia. Semin Oncol 1997; 24(suppl 16):35-42.
23. Fine PG. Fentanyl in the treatment of cancer pain. Semin Oncol 1997; 24 (suppl. 16):20-27.
24. Cleary JF. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol 1997; 24 (suppl. 16):13-19.
25. Kunz KM, Theisen JA, Schroeder ME. Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage 1993; 8:189.
26. Rosow C. Remifentanil: a unique opioid analgesic. Anethesiology 1993; 79:875-876.
27. Keating HJ, Kundrat M. Patient-controlled analgesia with nitrous oxide in cancer pain. J Pain Symptom Manage 1996; 11:126-130.
28. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334:488-493.
29. Thurlimann B, Morant R, Jungi WF, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2:61-65.
30. Luczak J, Dickenson AH, Kotlinska-Lemieszek A. The role of ketamine, an NMDA receptor antagonist, in the management of pain. Progress Palliat Care 1995; 3:127-134.
31. Persson J, Axelsson G, Hallin RG, Gustafsson LL. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to a central sensitization. Pain 1995; 60:217-222.
32. Mercadante S, Sapio M, Villari P. Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Reg Anesth 1995; 20:343-346.
33. Cooper MG, Keneally JP, Kinchington D. Continuous brachial plexus neural blockade in a child with intactable cancer pain. J Pain Symptom Manage 1994; 9:277-281.
34. Sato S, Yamashita S, Iwai M, et al. Continuous interscalene block for cancer pain. Reg Anesth 1994; 19:73-75.
35. Woodham MJ, Hanna M, Psoas compartment block in malignant pain. Pain Clin 1988; 2:219-224.
36. Aguilar JL, Montes A, Samper D, et al. Interpleural analgesia through a Du Pen catheter in lung cancer pain. Cancer 1992; 70:2621-2623.
37. Myers DP, Lema MJ, de Leon-Casasola OA, et al. Interpleural analgesia for the treatment of severe cancer pain in terminally ill patients. J Pain Symptom Manage 1993; 8:505-510.
38. Samuelsson H, Hedner T. Pain characterization in cancer patients and the analgesic response to epidural morphine. Pain 1991; 46:3-8.
39. Bloomfield S, Hogg J, Ortiz O, et al. Analysis of breakthrough pain in 50 patients treated with intrathecal morphine infusion therapy. Development of tolerance or infusion system malfunction. Stereotact Funct Neurosurg 1995; 65:142-146.
40. Du Pen SL, Kharash ED, Williams A, et al. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 1992; 49:293-300.
41. Nitescu P, Appelgren L, Linder LE, et al. Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain. J Pain Symptom Manage 1990; 5:18-26.
42. Mercadante S. Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J Pain Symptom Manage 1994; 9:201-207.
43. Sjoberg M, Nitescu P, Appelgren L, et al. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Anesthesiology 1994; 80:284-297.
44. Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. Pain 1995; 61:391-399.
45. Pellerin M, Hardy F, Abergel A, et al. Douleur chronique rebelles des cancereux. Interet de l'injetion intrarachidienne d'acétylsalycylate de lysine. Soixante observations. Presse Med 1987; 30:1465-1469.
46. Mercadante S. Effects of intrathecal lysine acetylsalicylate in intractable cancer pain. Pain Digest 1995; 5:181-186.
47. Tasker RR. Neurosurgical and neuroaugmentative intervention. In: RB. Patt (Ed), Cancer pain. JB Lippincott Co, Philadelphia, 1993, pp 471-500.
48. Ischia S, Ischia A, Luzzani A, et al. Results up to death in the treatment of persistent cervico-thoracic (Pancoast) and thoracic malignant pain by unilateral percutaneous cervical cordotomy. Pain 1985; 21:339-355.
49. Lipton S. Percutaneous cordotomy. In: Wall PD, Melzack R. (Eds), Textbook of pain, Churchill Livingstone, Edinburgh, 1989, pp 832-839.
50. Nagaro T, Amakawa K, Yamauchi Y, et al. Percutaneous cervical cordotomy and subarachnoid phenol block using fluroscopy in pain control of costopleural syndrome. Pain 1994; 58:325-330.
51. Ferrer-Brechner T. Rational management of cancer-related pain. In: RP Ray (Ed), Practical management of pain. Year Book Medical Publishers Inc, Chicago, 1986, pp 312-328.
52. Montejo Rosas G, Bruera E. Palliative care in Mexico: coeliac plexus block for incidental visceral pain. J Palliat Care 1993; 8; 35-36.
53. Hoskin PJ. Radiotherapy for bone pain. Pain 1995; 63:137-139.
54. Latini P, Maranzano E, Ricci S, et al. Role of radiotherapy in metastatic spinal cord compression: preliminary results from a prospective trial. Radiother Oncol 1989; 15:227-233.
55. Hanks GW, Justins DM. Cancer pain: management. Lancet 1992; 339:1031-1036.